NVCRN Stock Chart & Stats
$264.01
$0.00(0.00%)
At close: 4:00 PM EDT
$264.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$207.00 - $322.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$34.25B
Enterprise Value$1.54B
Total Cash (Recent Filing)$440.56M
Total Debt (Recent Filing)$233.42M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Oct 29, 2026EPS Estimate
-4.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding116,445,840
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$621.26Price Target Upside135.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-23.12
Revenue Forecast (FY)$13.59B
Bulls Say, Bears Say
Bulls Say
Revenue And Patient GrowthStrong revenue and active-patient growth indicate expanding adoption of NovoCure’s recurring therapy model across key markets. Continued patient gains can support durable revenue growth because usage-based treatment generates ongoing device and consumable demand rather than relying only on one-time sales.
Improving Margins And Operating EfficiencyThe sharp improvement in gross margin and adjusted EBITDA shows operating leverage as revenue scales and costs are managed. Management expects gross margins in the mid-70s through year-end, suggesting stronger economics may persist beyond a single quarter despite remaining profitability work.
Japanese Approval Expands Market ReachJapanese approval materially expands Optune Pax’s addressable market and supports broader global commercialization of TTFields. The reported survival benefit provides clinically meaningful evidence that may help physician adoption, payer discussions, and treatment uptake in an important cancer market.
Bears Say
Persistent Losses And Negative Free Cash FlowNovoCure has not yet converted its strong gross-margin profile into sustainable GAAP profitability or positive free cash flow. Continued losses and cash burn can constrain investment in launches and clinical programs, while increasing dependence on operating improvement and available funding.
Reimbursement And Contracting BarriersReimbursement and contracting requirements can slow patient access even after regulatory approval, delaying conversion of clinical progress into revenue. Hospital-level negotiations and country-specific treatment rules may therefore make international launches less predictable and raise the execution burden.
Early Adoption Requires Repeat PrescribersThe high share of single-time prescribers suggests early Optune Pax demand has not yet proven repeatable. NovoCure must demonstrate recurring physician use and sustained patient volume for the launch to become a durable growth driver rather than an initially strong but limited adoption cycle.
NovoCure News
NVCRN FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $207.00 and its highest was $322.39 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $34.25B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Jul 23, 2026. The company reported -$2.434 earnings per share for the quarter, beating the consensus estimate of -$6.216 by $3.782.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -4.4.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 116,445,840 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$2.434 in its last earnings report, beating expectations of -$6.216. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in MX:NVCRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$621.26 (135.32% Upside)
$621.26 (135.32% Upside)
Blogger Sentiment
Bullish
MX:NVCRN Sentiment 78%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.94%
12-Months-Change
Fundamentals
Return on Equity
-44.00%
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCRN Company Deck
NVCRN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum highlighted by record net revenue (+16% YoY), active patient growth (Optune Gio +11% YoY), successful early launches (Optune Pax and Optune Lua), and a return to positive adjusted EBITDA in the quarter. Management also emphasized disciplined cost-management actions (R&D reductions and LUNAR-2 optimization) and updated full-year guidance reflecting confidence in continued progress. Key challenges include reimbursement and contracting hurdles (EU and Japan), reliance on some one-time benefits in Q2, the need to convert one-time prescribers into repeat prescribers for sustained growth, and clinical trial redesign risks. Overall, the positives — stronger commercial performance, profitability trajectory, regulatory milestones and clear launch progress — meaningfully outweigh the identified lowlights.View all MX:NVCRN earnings summariesNVCRN Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCRN Stock 12 Month Forecast
Average Price Target
$621.26
▲(135.32% Upside)
Technical Analysis
Accuray
―
Delcath Systems
―
Perspective Therapeutics
―
Sensus Healthcare
―
TriSalus Life Sciences
―